MedPath

Safety and efficacy of Irsal-i-Alaq (Leeching) in Waja-al- Rukba (Knee steoarthritis)

Phase 2
Conditions
Health Condition 1: null- Osteoarthritis of Knee Joint
Registration Number
CTRI/2017/04/008382
Lead Sponsor
Jamia Hamdard
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Patients of Knee OA in age groups of 35 years to 65 years.

Subjective pain intensity of 20 mm or more at baseline on Visual Analogue Scale (VAS).

Clinically stable patients.

Patients of both sexes.

Patients willing to sign the informed consent form and participate in the trial voluntarily.

Exclusion Criteria

Diabetes mellitus Type 1 and uncontrolled Type 2.

Active hepatic disease, abnormal liver function. (Alanine transaminase, Aspartate transaminase or Total bilirubin level more than twice normal values), or renal dysfunction (blood creatinine over the upper limit of normal).

Current anticoagulant therapy or bleeding disorders or Severe Anaemia.

Pregnant and lactating mothers.

ESR > 40 mm/hr.

Terminally ill patients.

Patients below 35 years and above 65 years of age.

Patients who fail to give consent.

Subjects who had received leeching to the knee region 1 months prior to the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Visual Analogue Scale (VAS). <br/ ><br>WOMAC Index (Modified â?? CRD Pune Version) / KOOS <br/ ><br>Active range of motion using Goniometer. <br/ ><br>Rescue medication use <br/ ><br>X ray Knee AP & Lateral views (Kellgren -Lawrence Grading Scale). <br/ ><br>Urinary Pyridinoline (Pyd) <br/ ><br>Timepoint: Visual Analogue Scale (VAS)at Day Zero and 28th day <br/ ><br>WOMAC Index (Modified â?? CRD Pune Version) / KOOS at Day Zero and 28th day <br/ ><br>Active range of motion using Goniometer at day Zero and 28th day <br/ ><br>Rescue medication use from Day zero upto 28th day <br/ ><br>X ray Knee AP & Lateral views (Kellgren -Lawrence Grading Scale)at day zero and 28th day <br/ ><br>Urinary Pyridinoline (Pyd) at day zero and 28th day
Secondary Outcome Measures
NameTimeMethod
I.To evaluate the effect of Irsal-i-Alaq (Leeching) on the progression of disease process in Waja-al-Rukba (knee OA) patients.Timepoint: Base line and 28th day
© Copyright 2025. All Rights Reserved by MedPath